Cargando…
Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma
BACKGROUND/AIMS: The diagnosis and treatment plan for hepatocellular carcinoma (HCC) can be made from radiologic imaging. However, lesion detection may vary depending on the imaging modality. This study aims to evaluate the sensitivities of hepatic multidetector computed tomography (MDCT), magnetic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266349/ https://www.ncbi.nlm.nih.gov/pubmed/27987537 http://dx.doi.org/10.3350/cmh.2016.0036 |
_version_ | 1782500452506533888 |
---|---|
author | Ladd, Lauren M. Tirkes, Temel Tann, Mark Agarwal, David M. Johnson, Matthew S. Tahir, Bilal Sandrasegaran, Kumaresan |
author_facet | Ladd, Lauren M. Tirkes, Temel Tann, Mark Agarwal, David M. Johnson, Matthew S. Tahir, Bilal Sandrasegaran, Kumaresan |
author_sort | Ladd, Lauren M. |
collection | PubMed |
description | BACKGROUND/AIMS: The diagnosis and treatment plan for hepatocellular carcinoma (HCC) can be made from radiologic imaging. However, lesion detection may vary depending on the imaging modality. This study aims to evaluate the sensitivities of hepatic multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), and digital subtraction angiography (DSA) in the detection of HCC and the consequent management impact on potential liver transplant patients. METHODS: One hundred and sixteen HCC lesions were analyzed in 41 patients who received an orthotopic liver transplant (OLT). All of the patients underwent pretransplantation hepatic DSA, MDCT, and/or MRI. The imaging results were independently reviewed retrospectively in a blinded fashion by two interventional and two abdominal radiologists. The liver explant pathology was used as the gold standard for assessing each imaging modality. RESULTS: The sensitivity for overall HCC detection was higher for cross-sectional imaging using MRI (51.5%, 95% confidence interval [CI]=36.2-58.4%) and MDCT (49.8%, 95% CI=43.7-55.9%) than for DSA (41.7%, 95% CI=36.2-47.3%) (P=0.05). The difference in false-positive rate was not statistically significant between MRI (22%), MDCT (29%), and DSA (29%) (P=0.67). The sensitivity was significantly higher for detecting right lobe lesions than left lobe lesions for all modalities (MRI: 56.1% vs. 43.1%, MDCT: 55.0% vs. 42.0%, and DSA: 46.9% vs. 33.9%; all P<0.01). The sensitivities of the three imaging modalities were also higher for lesions ≥2 cm vs. <2 cm (MRI: 73.4% vs. 32.7%, MDCT: 66.9% vs. 33.8%, and DSA: 62.2% vs. 24.1%; all P<0.01). The interobserver correlation was rated as very good to excellent. CONCLUSION: The sensitivity for detecting HCC is higher for MRI and MDCT than for DSA, and so cross-sectional imaging modalities should be used to evaluate OLT candidacy. |
format | Online Article Text |
id | pubmed-5266349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-52663492017-01-26 Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma Ladd, Lauren M. Tirkes, Temel Tann, Mark Agarwal, David M. Johnson, Matthew S. Tahir, Bilal Sandrasegaran, Kumaresan Clin Mol Hepatol Original Article BACKGROUND/AIMS: The diagnosis and treatment plan for hepatocellular carcinoma (HCC) can be made from radiologic imaging. However, lesion detection may vary depending on the imaging modality. This study aims to evaluate the sensitivities of hepatic multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), and digital subtraction angiography (DSA) in the detection of HCC and the consequent management impact on potential liver transplant patients. METHODS: One hundred and sixteen HCC lesions were analyzed in 41 patients who received an orthotopic liver transplant (OLT). All of the patients underwent pretransplantation hepatic DSA, MDCT, and/or MRI. The imaging results were independently reviewed retrospectively in a blinded fashion by two interventional and two abdominal radiologists. The liver explant pathology was used as the gold standard for assessing each imaging modality. RESULTS: The sensitivity for overall HCC detection was higher for cross-sectional imaging using MRI (51.5%, 95% confidence interval [CI]=36.2-58.4%) and MDCT (49.8%, 95% CI=43.7-55.9%) than for DSA (41.7%, 95% CI=36.2-47.3%) (P=0.05). The difference in false-positive rate was not statistically significant between MRI (22%), MDCT (29%), and DSA (29%) (P=0.67). The sensitivity was significantly higher for detecting right lobe lesions than left lobe lesions for all modalities (MRI: 56.1% vs. 43.1%, MDCT: 55.0% vs. 42.0%, and DSA: 46.9% vs. 33.9%; all P<0.01). The sensitivities of the three imaging modalities were also higher for lesions ≥2 cm vs. <2 cm (MRI: 73.4% vs. 32.7%, MDCT: 66.9% vs. 33.8%, and DSA: 62.2% vs. 24.1%; all P<0.01). The interobserver correlation was rated as very good to excellent. CONCLUSION: The sensitivity for detecting HCC is higher for MRI and MDCT than for DSA, and so cross-sectional imaging modalities should be used to evaluate OLT candidacy. The Korean Association for the Study of the Liver 2016-12 2016-12-14 /pmc/articles/PMC5266349/ /pubmed/27987537 http://dx.doi.org/10.3350/cmh.2016.0036 Text en Copyright © 2016 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ladd, Lauren M. Tirkes, Temel Tann, Mark Agarwal, David M. Johnson, Matthew S. Tahir, Bilal Sandrasegaran, Kumaresan Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title_full | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title_fullStr | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title_full_unstemmed | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title_short | Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
title_sort | comparison of hepatic mdct, mri, and dsa to explant pathology for the detection and treatment planning of hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266349/ https://www.ncbi.nlm.nih.gov/pubmed/27987537 http://dx.doi.org/10.3350/cmh.2016.0036 |
work_keys_str_mv | AT laddlaurenm comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT tirkestemel comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT tannmark comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT agarwaldavidm comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT johnsonmatthews comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT tahirbilal comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma AT sandrasegarankumaresan comparisonofhepaticmdctmrianddsatoexplantpathologyforthedetectionandtreatmentplanningofhepatocellularcarcinoma |